COMP <GO>
ETON vs MRK // FREE CASH FLOW YIELD
Eton Pharmaceuticals Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: ETON 3
— MRK 7
▲ FREE CASH FLOW YIELD LEADER: MRK
LAST: $52.18 (-2.78%) • MKT CAP: $1.53B
fcf-yield
0.66%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
fcf-yield
3.42%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ETON VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ETON | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 53.50% | 74.80% | -21.30 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -0.90% | 20.70% | -21.60 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 0.66% | 3.42% | -2.76 | MRK | /fcf-yield <GO> |
| Operating Margin | -1.10% | 34.30% | -35.40 | MRK | /operating-margins <GO> |
| Net Profit Margin | -5.80% | 28.10% | -33.90 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 104.90% | 1.30% | +103.60 | ETON | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 13.37 | 5.19 | +8.18 | ETON | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.8 | 51.7 | +1.10 | ETON | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.53B | $361.02B | -$359.49B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ETON REV | MRK REV | ETON GROSS % | MRK GROSS % | ETON FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $80.0M | $65.01B | 53.5% | 74.8% | $10.2M | $12.36B |
| FY 2024 | $39.0M | $64.17B | 60.0% | 76.3% | $943.0K | $18.10B |
| FY 2023 | $31.6M | $60.12B | — | — | $6.8M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ETON // BETA —
MRK // BETA 0.92